The Korean health insurance policy was updated in July 2020, to include TNBC patients aged 60 or under for BRCA1/2 mutation testing, and the currently applied 10th Korean clinical practice guideline for breast cancer has identical BRCA1/2 mutation testing recommendations for TNBC patients25. This evidence concerns the gene BRCA1 and breast cancer.